DN
DNA.US Ginkgo Bioworks Holdings
- Market cap
- USD 623M
- P/E
- -
- P/B
- 1.69x
- ROE
- -57.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DNA.US undervalued?
Graham numberThe Graham number of Ginkgo Bioworks Holdings cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ginkgo Bioworks Holdings fundamental analysis
No fundamental analysis for Ginkgo Bioworks Holdings yet.
Ginkgo Bioworks Holdings stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platf…
Full company profileGinkgo Bioworks Holdings financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ginkgo Bioworks Holdings annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 54.2M | 76.7M | 314M | 478M | 251M | 227M | 170M | 89.8M |
| Gross Profit | 54.2M | 61.0M | 184M | 273M | 197M | 188M | 139M | 63.9M |
| Operating Income | -71.6M | -137M | -1.83B | -2.21B | -864M | -560M | -315M | -231M |
| EBITDA | -107M | -109M | -1.81B | -2.08B | -821M | -484M | -255M | -199M |
| Net Income | -119M | -127M | -1.83B | -2.10B | -893M | -547M | -313M | -227M |
| EPS | -4.15 | -3.97 | -54 | -50 | -18 | -11 | -5.64 | -3.55 |
| Balance Sheet | ||||||||
| Total Assets | 697M | 675M | 2.07B | 2.54B | 1.67B | 1.38B | 1.12B | 944M |
| Total Liabilities | 195M | 205M | 504M | 803M | 568M | 661M | 611M | 552M |
| Shareholders' Equity | 493M | 461M | 1.51B | 1.74B | 1.10B | 716M | 509M | 393M |
| Cash & Short-term Investments | 495M | 381M | 1.55B | 1.32B | 944M | 562M | 423M | 285M |
| Total Debt | 17.4M | 17.0M | 23.0M | 443M | 239M | 468M | 440M | 397M |
| Cash Flow | ||||||||
| Operating Cash Flow | -44.7M | -136M | -254M | -252M | -296M | -320M | -171M | -159M |
| Capital Expenditure | 22.2M | 57.8M | 56.5M | 52.3M | 40.8M | 62.5M | 7.67M | 8.74M |
| Free Cash Flow | -66.9M | -194M | -310M | -304M | -336M | -382M | -179M | -165M |
| Ratios | ||||||||
| ROE | -24.2% | -27.4% | -121.6% | -121.2% | -81.4% | -76.4% | -61.5% | -57.8% |
| ROA | -17.1% | -18.8% | -88.4% | -82.9% | -53.6% | -39.7% | -27.9% | -24.0% |
| Net Profit Margin | -220.2% | -165.2% | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% | -252.9% |
| Debt to Equity | 0.04x | 0.04x | 0.02x | 0.25x | 0.22x | 0.65x | 0.86x | 1.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ginkgo Bioworks Holdings dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 981K | 0.02 | - |
| 2021 | USD 1.51B | 44 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:40 on Aug 20, 2024.
Who owns Ginkgo Bioworks Holdings
- Insiders 5.44%
- Institutions 79.75%
- Public & others 14.81%
- Shares outstanding 53.9M
- Free float 48.6M
Top funds holding DNA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Scottish Mortgage Ord | 2.39M | 3.55% | 0.00% | Jul 2026 |
| L&G Artificial Intelligence ETF | 1.81M | 2.69% | +0.10% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.49M | 2.21% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.22M | 1.82% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 549K | 0.82% | +4.96% | Aug 2026 |
| PIMCO RAE US S Instl | 506K | 0.75% | +3.46% | Jun 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 467K | 0.69% | +99.17% | Sep 2026 |
| iShares Russell 2000 Value ETF | 446K | 0.66% | 0.00% | Oct 2026 |
| Robo Global® Artificial Intelligence ETF | 420K | 0.62% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 378K | 0.56% | -0.19% | Oct 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 327K | 0.48% | +0.08% | Oct 2026 |
| Vanguard Russell 2000 ETF | 277K | 0.41% | +1.46% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 271K | 0.40% | +0.24% | Oct 2026 |
| Vanguard Explorer Inv | 251K | 0.37% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 245K | 0.36% | -1.99% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 163K | 0.24% | 0.00% | Oct 2026 |
| LVIP FranklinTempletonMltFctSMIDCapEqStd | 154K | 0.23% | +823.73% | Sep 2026 |
| iShares Micro-Cap ETF | 144K | 0.21% | 0.00% | Oct 2026 |
| iShares Genomics Immnlgy & Hlthcr ETF | 135K | 0.20% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 123K | 0.18% | +0.11% | Sep 2026 |
Top institutions holding DNA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.28M | 6.36% | +17.59% | Jun 2026 |
| Viking Global Investors LP | 3.58M | 5.31% | 0.00% | Jun 2026 |
| Erste Asset Management GmbH | 2.54M | 3.77% | +30.25% | Jun 2026 |
| Baillie Gifford & Co Limited. | 2.39M | 3.55% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.09M | 3.10% | +9.03% | Jun 2026 |
| Anchorage Advisors, LLC | 1.75M | 2.59% | 0.00% | Jun 2026 |
| Legal & General Group PLC | 1.67M | 2.48% | +0.47% | Jun 2026 |
| State Street Corp | 1.47M | 2.19% | +9.34% | Jun 2026 |
| Geode Capital Management, LLC | 1.22M | 1.81% | +21.07% | Jun 2026 |
| Forbes J M & Co | 977K | 1.45% | -2.25% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 938K | 1.39% | +65.79% | Jun 2026 |
| Allianz Asset Management AG | 786K | 1.17% | +12.17% | Jun 2026 |
| UBS Group AG | 692K | 1.03% | +18.68% | Jun 2026 |
| Millennium Management LLC | 639K | 0.95% | +30.89% | Jun 2026 |
| AQR Capital Management LLC | 622K | 0.92% | +110.87% | Jun 2026 |
| SB INVESTMENT ADVISERS (UK) LTD | 611K | 0.91% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 607K | 0.90% | -34.68% | Jun 2026 |
| Bank of America Corp | 546K | 0.81% | +14.46% | Jun 2026 |
| Prescott Group Capital Management LLC | 542K | 0.80% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 540K | 0.80% | +437.41% | Jun 2026 |
Ginkgo Bioworks Holdings company profile
- Company name
- Ginkgo Bioworks Holdings
- Ticker
- DNA.US
- Exchange
- USA Stocks
- Listed since
- Apr 19, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 485
- Fiscal year end
- December
- Address
- 27 Drydock Avenue, Boston, MA, United States, 02210
- Phone
- 877 422 5362
- Website
- ginkgo.bio
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Ginkgo Bioworks Holdings management
10- Dr. Jason Kelly Ph.D.Co-Founder, Co-COO, CEO & Director · born 1981
- Dr. Reshma P. ShettyCo-Founder, President & Director · born 1981
- Mr. Steven P. Coen CPAChief Financial Officer · born 1966
- Mr. Thomas Knight Jr.Founder
- Mr. Austin Che Ph.D.Co-Founder & Head of Strategy
- Mr. Bartholomew Canton Ph.D.Co-Founder & CTO
- Ms. Jennifer WipfCo-Chief Operating Officer
- Ms. Karen TepichinGeneral Counsel & Secretary
- Mr. Daniel MarshallSenior Manager of Communications & Ownership
- Mr. Brian O'sullivanHead of Commercial